Enveric Biosciences (ENVB) Current Assets (2010 - 2026)
Enveric Biosciences (ENVB) posted Current Assets of $5.4 million for Q1 2026, up 8.88% sequentially from $4.9 million in Q4 2025, and up 11.17% YoY from $4.8 million in Q1 2025.
Enveric Biosciences (ENVB) Current Assets (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Current Assets for 17 years, with the latest figure at $5.4 million in Q1 2026.
- Quarterly Current Assets rose 11.17% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 11.17% YoY) and the FY2025 annual result came in at $4.9 million, up 80.53% from the prior year.
- Current Assets rose to $5.4 million in Q1 2026 per ENVB's latest filing, from $4.9 million in the prior quarter.
- Over five years, Current Assets peaked at $22.7 million in Q1 2022 and troughed at $2.7 million in Q4 2024.
- A 5-year average of $9.4 million and a median of $5.5 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets sank 80.57% in 2023, then surged 80.53% in 2025.
- Over 5 years, Current Assets stood at $18.4 million in 2022, then tumbled by 80.57% to $3.6 million in 2023, then retreated by 23.65% to $2.7 million in 2024, then soared by 80.53% to $4.9 million in 2025, then gained by 8.88% to $5.4 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $5.4 million, $4.9 million, and $4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 1.76 Bn |
| 10 | Enveric Biosciences | 5.64 Mn | -2.65 Mn | - | 8.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.38 Mn |
| Dec 31, 2025 | 4.94 Mn |
| Sep 30, 2025 | 4.17 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | 4.83 Mn |
| Dec 31, 2024 | 2.73 Mn |
| Sep 30, 2024 | 4.34 Mn |
| Jun 30, 2024 | 5.52 Mn |
| Mar 31, 2024 | 8.23 Mn |
| Dec 31, 2023 | 3.58 Mn |
| Sep 30, 2023 | 5.83 Mn |
| Jun 30, 2023 | 8.90 Mn |
| Mar 31, 2023 | 14.84 Mn |
| Dec 31, 2022 | 18.43 Mn |
| Sep 30, 2022 | 22.27 Mn |
| Jun 30, 2022 | 19.37 Mn |
| Mar 31, 2022 | 22.67 Mn |
| Dec 31, 2021 | 17.74 Mn |
| Sep 30, 2021 | 22.28 Mn |
| Jun 30, 2021 | 21.51 Mn |